Zhejiang Chimin Pharm Co Ltd Net Asset Quality Index
Zhejiang Chimin Pharm Co Ltd net asset quality index. Zhejiang Chimin Pharm Co Ltd (603222) has a Net Asset Quality Index of 53.1% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.21 Billion minus total liabilities of CN¥1.04 Billion yields net assets of CN¥1.17 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check cash flow quality index of Zhejiang Chimin Pharm Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Zhejiang Chimin Pharm Co Ltd (2011–2025)
Net asset quality index of Zhejiang Chimin Pharm Co Ltd from 2011 to 2025. This chart shows how Zhejiang Chimin Pharm Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 53.1%, representing net assets of CN¥1.17 Billion against total assets of CN¥2.21 Billion CNY. See 603222 net asset value for net asset value and shareholders' equity analysis.
Zhejiang Chimin Pharm Co Ltd Net Asset Quality Index by Year (2011–2025)
Zhejiang Chimin Pharm Co Ltd net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Zhejiang Chimin Pharm Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Zhejiang Chimin Pharm Co Ltd market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 56.5% | CN¥1.31 Billion | CN¥2.31 Billion | CN¥1.00 Billion | ▼ -8.4 pp |
| 2024 | 65.0% | CN¥1.57 Billion | CN¥2.41 Billion | CN¥846.22 Million | ▼ -2.0 pp |
| 2023 | 66.9% | CN¥1.66 Billion | CN¥2.48 Billion | CN¥820.13 Million | ▲ +1.6 pp |
| 2022 | 65.4% | CN¥1.77 Billion | CN¥2.71 Billion | CN¥939.64 Million | ▲ +8.7 pp |
| 2021 | 56.7% | CN¥1.37 Billion | CN¥2.43 Billion | CN¥1.05 Billion | ▲ +11.0 pp |
| 2020 | 45.6% | CN¥1.05 Billion | CN¥2.29 Billion | CN¥1.25 Billion | ▼ -5.8 pp |
| 2019 | 51.5% | CN¥1.07 Billion | CN¥2.08 Billion | CN¥1.01 Billion | ▲ +2.2 pp |
| 2018 | 49.3% | CN¥1.05 Billion | CN¥2.12 Billion | CN¥1.08 Billion | ▼ -9.7 pp |
| 2017 | 58.9% | CN¥928.28 Million | CN¥1.57 Billion | CN¥646.63 Million | ▼ -28.8 pp |
| 2016 | 87.7% | CN¥808.94 Million | CN¥922.43 Million | CN¥113.49 Million | ▼ -1.3 pp |
| 2015 | 89.0% | CN¥750.99 Million | CN¥844.01 Million | CN¥93.02 Million | ▲ +18.9 pp |
| 2014 | 70.1% | CN¥441.55 Million | CN¥630.04 Million | CN¥188.49 Million | ▲ +1.7 pp |
| 2013 | 68.4% | CN¥488.13 Million | CN¥713.38 Million | CN¥225.24 Million | ▲ +5.8 pp |
| 2012 | 62.6% | CN¥432.53 Million | CN¥690.63 Million | CN¥258.10 Million | ▲ +4.2 pp |
| 2011 | 58.5% | CN¥383.04 Million | CN¥655.30 Million | CN¥272.26 Million | — |